GHK-Cu vs Hexarelin

GHK-Cu and Hexarelin represent two distinct classes of research peptides with limited mechanistic overlap. GHK-Cu is a naturally occurring copper-binding tripeptide involved in wound healing, collagen synthesis, and gene modulation, supported by decades of clinical and cosmetic use. Hexarelin is a synthetic growth hormone secretagogue that acts via the ghrelin receptor to stimulate potent GH release, with additional cardioprotective properties. This comparison examines their mechanisms, evidence bases, dosing protocols, and safety profiles to clarify when each may be more appropriate for specific research objectives.

GHK-Cu (glycyl-L-histidyl-L-lysine) is a naturally occurring tripeptide that binds copper, first identified by Dr. Loren Pickart in 1973. Plasma levels average 200 ng/mL at age 20 but decline to approximately 80 ng/mL by age 60, suggesting a role in age-related tissue decline. Its mechanism involves modulating gene expression—upregulating collagen, elastin, and proteoglycan synthesis while downregulating inflammatory cytokines. Research indicates it promotes wound healing, improves skin firmness and elasticity, and reduces fine lines and wrinkles. The evidence base is robust, with decades of cosmetic use and clinical studies, including a 2018 review (PMID: 29986520) highlighting its safety and efficacy. Molecular weight is approximately 340 g/mol as the copper complex (C14H24N6O4Cu).

Hexarelin is a synthetic hexapeptide growth hormone secretagogue that binds to the ghrelin receptor (GHS-R1a). It is considered one of the most potent GHRPs available, stimulating greater GH release than GHRH alone. However, it causes relatively rapid receptor desensitization compared to milder GHRPs like ipamorelin, limiting cycle duration to 4-8 weeks. It also has notable cardioprotective properties independent of GH release.

Key claims: Potent GH release; Cardioprotective effects; Improves body composition.

Both peptides are studied for anti-aging, but their approaches differ fundamentally. GHK-Cu targets tissue repair and regeneration through direct modulation of extracellular matrix components, making it relevant for skin health and wound healing. Hexarelin influences systemic aging via the GH/IGF-1 axis, with additional research into body composition changes. GHK-Cu is also researched for skin health and wound healing, while Hexarelin is studied for body composition. Researchers should consider whether their focus is on local tissue regeneration or systemic hormonal modulation.

GHK-Cu has an excellent safety profile, with minimal side effects reported in decades of cosmetic and clinical use (PMID: 29986520). Topical forms are generally well-tolerated; mild skin irritation is rare and typically limited to very sensitive skin. Injectable forms may cause mild injection site reactions, lightheadedness, nausea, or flu-like symptoms; rotating injection sites reduces local irritation. Hexarelin is generally well-tolerated in clinical trials, but transient cortisol and prolactin elevation can occur at higher doses. Hunger increase is common due to ghrelin receptor activation. Researchers should monitor for hormonal fluctuations and consider the desensitization risk when designing study protocols.